eleven
year
ago
world
shock
outbreak
sever
acut
respiratori
syndrom
sar
spread
origin
southern
chines
provinc
guangdong
hong
kong
countri
world
vietnam
singapor
taiwan
canada
toronto
affect
also
viru
travel
hong
kong
beij
alon
sar
case
record
altogeth
case
regist
worldwid
surviv
sar
character
atyp
sever
pneumonia
recent
review
commemor
sar
outbreak
discuss
lesson
learn
see
march
new
coronaviru
appropri
name
sar
coronaviru
describ
etiolog
agent
caus
epidem
viru
rapidli
classifi
outlier
call
group
coronavirus
time
accord
new
nomenclatur
introduc
year
later
see
exampl
belong
clade
b
genu
betacoronaviru
follow
sar
epidem
two
new
human
coronavirus
discov
due
intensifi
research
effort
target
previous
neglect
viru
famili
human
coronaviru
member
genu
alphacoronaviru
describ
follow
discoveri
hcov
betacoronaviru
year
later
virus
widespread
caus
sever
diseas
major
peopl
infect
septemb
anoth
novel
human
coronaviru
middl
east
respiratori
syndrom
mer
coronaviru
describ
detect
patient
saudi
arabia
countri
arab
peninsula
peopl
histori
travel
middl
east
earliest
cluster
mer
case
detect
far
jordan
april
shown
retrospect
basi
patient
sampl
symptom
mer
includ
sever
respiratori
diseas
often
renal
failur
juli
case
record
death
http
wwwwhoint
ratio
mer
thu
alarmingli
high
case
wild
anim
palm
civet
sold
delicaci
chines
wet
market
initi
identifi
immedi
sourc
viru
insectivor
rhinolophid
bat
came
focu
origin
reservoir
viru
possibl
transmit
civet
market
speci
human
see
recent
review
bat
coronavirus
howev
took
discov
bat
coronaviru
ident
use
receptor
surfac
host
cell
enzym
case
mer
coronaviru
bat
suspect
reservoir
coronavirus
high
sequenc
similar
discov
african
european
bat
recent
month
pictur
chang
somewhat
dromedari
camel
main
suspect
reservoir
zoonot
transmiss
human
popul
origin
sar
epidem
mani
scientist
includ
even
mani
virologist
believ
event
uniqu
chanc
repetit
extrem
low
thu
must
said
effort
could
made
develop
compound
activ
hamper
howev
sharp
declin
fund
coronaviru
research
mani
countri
lack
support
scientif
commun
consequ
lesson
sar
outbreak
taught
us
taken
serious
discuss
recent
still
continu
emerg
illustr
event
happen
anywher
time
given
larg
number
coronaviru
speci
natur
probabl
know
fraction
far
coronavirus
featur
largest
rna
genom
kb
fig
known
genom
extrem
flexibl
term
incorpor
delet
gene
product
respons
evolutionari
pressur
need
adapt
new
host
coronaviru
genom
also
prone
recombin
event
therebi
ad
flexibl
review
illumin
question
whether
macromolecular
crystallographi
contribut
discoveri
antivir
target
protein
new
virus
focu
main
antivir
drug
target
coronaviru
main
proteas
mpro
also
call
proteas
proteas
plpro
enzym
coronavirus
helicas
rna
polymeras
also
target
antivir
drug
discoveri
effort
limit
far
lack
crystal
structur
enzym
see
recent
review
coronavir
proteas
mpro
plpro
respons
process
huge
polyprotein
encod
open
read
frame
coronaviru
genom
matur
protein
nsp
form
part
coronavir
replicationtranscript
complex
fig
inform
protein
structur
see
mpro
encod
protein
respons
less
cleavag
site
polyprotein
fig
flank
protein
along
part
anchor
replicationtranscript
complex
vesicl
deriv
endoplasm
reticulum
membran
infect
substrat
cleavag
mpro
follow
gener
pattern
small
lfm
ga
x
amino
acid
cleavag
site
particular
glutamin
q
residu
posit
substrat
absolut
requir
proteas
known
specif
prospect
come
without
mani
actual
good
group
start
work
coronaviru
mpro
around
time
singl
crystal
structur
coronaviru
protein
determin
first
elucid
crystal
structur
mpro
transmiss
gastroenter
viru
tgev
porcin
coronaviru
fatal
young
piglet
publish
structur
reveal
mpro
dimer
cf
fig
one
monom
help
shape
pocket
oxyanion
hole
monom
henc
dimer
prerequisit
catalyt
activ
also
reveal
presenc
domain
domain
iii
addit
domain
ii
togeth
featur
fold
harbor
catalyt
dyad
subsequ
synthes
chloromethylketon
inhibitor
cocrystal
tgev
mpro
order
visual
site
detail
time
also
determin
structur
mpro
human
coronaviru
hcov
identifi
sequenc
spring
built
first
homolog
model
mpro
basi
structur
enzym
hcov
suggest
basi
bind
mode
chloromethylketon
inhibitor
michael
acceptor
compound
rupintrivir
develop
pfizer
inhibitor
proteas
human
rhinoviru
good
start
point
drug
design
later
compound
turn
particularli
high
activ
cell
cultur
deriv
michael
acceptor
lead
turn
exhibit
good
activ
vitro
ex
vivo
toward
end
sar
outbreak
beij
june
crystal
structur
main
proteas
determin
collabor
group
zihe
rao
beij
recombinantli
produc
crystal
enzym
group
free
proteas
fig
complex
chloromethylketon
inhibitor
alreadi
use
tgev
mpro
first
structur
free
mpro
determin
crystal
grown
acid
ph
around
structur
one
monom
mpro
dimer
activ
state
one
catalyt
incompet
conform
specif
pocket
oxyanion
hole
collaps
crystal
equilibr
buffer
ph
monom
found
activ
conform
wherea
ph
site
less
well
defin
due
increas
flexibl
amino
acid
involv
phenomenon
explain
molecular
dynam
simul
run
differ
proton
state
two
key
histidin
residu
involv
shape
site
profil
mpro
found
probabl
determin
proton
inactiv
acid
ph
deproton
inactiv
basic
ph
observ
catalyt
incompet
form
site
oxyanion
hole
collaps
occasion
ascrib
eg
presenc
five
addit
residu
remain
clone
procedur
phenomenon
observ
enzym
featur
authent
chain
termini
crystal
space
group
determin
structur
mpro
authent
chain
termini
crystal
grown
symmetri
observ
presenc
activ
inact
monom
low
ph
verschueren
et
al
unpublish
exist
less
activ
proform
enzym
may
allow
control
tempor
order
process
individu
polyprotein
cleavag
site
releas
intermedi
matur
nsp
time
replic
need
unfortun
ph
site
action
mpro
vesicl
known
liber
viral
polyprotein
mpro
integr
part
polyprotein
fig
mechan
enzym
well
understood
see
review
sever
studi
use
construct
carri
fluoresc
protein
termini
mpro
connect
enzym
peptid
sequenc
contain
mpro
cleavag
site
polyprotein
model
usual
monomer
dimer
format
upon
addit
substrat
observ
found
upon
mutat
three
residu
involv
interfac
matur
proteas
result
monomer
enzym
still
perform
autocleavag
dimer
activ
complet
inhibit
mutat
partli
mutat
furthermor
matur
mutant
resum
autocleavag
activ
mix
inact
mpro
speci
wherea
activ
remain
absent
therefor
autoprocess
mpro
appear
requir
two
immatur
monom
approach
one
anoth
form
intermedi
dimer
structur
depend
activ
dimer
conform
exist
matur
proteas
octamer
form
immatur
mpro
featur
swap
helic
domain
iii
enzym
may
play
role
process
larg
number
crystal
structur
publish
inhibitor
complex
mpro
mention
mani
type
chemic
warhead
use
achiev
coval
bind
peptid
peptidomimet
inhibitor
cystein
mpro
includ
halomethylketon
michael
acceptor
compound
ester
mention
aldehyd
nitril
phthalhydrazid
keton
compound
peptidomimet
carri
electrophil
warhead
sever
also
effici
inhibit
replic
cell
cultur
inhibitor
exampl
halomethylketon
certainli
reactiv
develop
drug
expect
exhibit
consider
one
might
intuit
assum
aldehyd
fact
peptid
aldehyd
inhibitor
thrombin
efegatran
show
toxic
clinic
trial
also
note
two
hepat
c
viru
proteas
inhibitor
introduc
market
telaprivir
boceprivir
peptidomimet
carri
warhead
final
rupintrivir
exampl
michael
acceptor
compound
develop
inhibitor
proteas
human
rhinoviru
trend
away
binder
target
serin
cystein
proteas
toward
coval
revers
irrevers
binder
given
absolut
requir
coronaviru
mpro
glutamin
posit
substrat
absenc
human
proteas
specif
good
chanc
develop
coronaviru
proteas
inhibitor
carri
electrophil
warhead
without
expect
mani
see
figur
show
bind
michael
acceptor
compound
origin
develop
enteroviru
proteas
complex
mpro
reveal
crystallographi
zhu
et
al
unpublish
pdb
code
http
wwwrcsborgpdbsearchstructidsearchdo
agreement
expect
outlin
compound
show
sign
toxic
vero
cell
respect
mice
leyssen
neyt
et
al
unpublish
exhibit
around
isol
mpro
replicon
vero
cell
zhu
kusov
muth
et
al
unpublish
addit
number
revers
inhibitor
main
proteas
discov
virtual
screen
andor
dock
basi
crystal
structur
exampl
compound
cinanserin
arylboron
acid
isatin
deriv
select
diarylsulfon
varieti
other
inhibitor
benzotriazol
ester
benzo
discov
screen
chemic
librari
subsequ
optim
hit
medicin
chemistri
chloropyridyl
ester
deriv
benzotriazol
ester
found
good
antivir
activ
cell
cultur
proteas
encod
genom
proteas
respons
process
three
cleavag
site
part
polyprotein
produc
matur
fig
cleavag
specif
plpro
correspond
pattern
rk
l
rk
addit
enzym
deubiquitinas
ie
remov
poli
ubiquitin
unit
protein
tag
ubiquitin
carri
sequenc
lrlrgg
perfect
agreement
coronaviru
plpro
recognit
motif
deubiquitinas
activ
enzym
interfer
unknown
way
phosphoryl
nuclear
import
factor
therebi
prevent
product
interferon
infect
host
cell
plpro
also
shown
activ
ie
remov
unit
target
protein
label
way
isg
gene
product
final
plpro
demonstr
interfer
nuclear
factor
pathway
ie
import
weapon
viru
effort
counteract
innat
immun
respons
infect
host
cell
crystal
structur
plpro
report
ratia
et
al
enzym
consist
ubl
domain
catalyt
core
domain
featur
fold
thumb
palm
finger
subdomain
tip
finger
domain
structur
zinc
ion
found
within
structur
fig
took
number
year
obtain
crystallin
complex
plpro
ubiquitin
recent
chou
et
al
publish
structur
complex
ubiquitin
plpro
catalyt
cystein
residu
replac
serin
ratia
et
al
report
structur
nativ
plpro
complex
ubiquitin
aldehyd
aldehyd
group
form
coval
bond
catalyt
enzym
use
peptidomimet
inhibitor
block
plpro
connect
difficulti
inhibitor
would
like
also
inhibit
deubiquitinas
sever
would
expect
therefor
search
inhibitor
plpro
focus
screen
chemic
librari
revers
inhibitor
enzym
way
ratia
et
al
ghosh
et
al
identifi
hit
compound
optim
yield
inhibitor
submicromolar
activ
isol
enzym
activ
cell
cultur
see
also
optim
reli
heavili
crystal
structur
complex
select
candid
inhibitor
plpro
sever
inhibitor
discov
way
eg
bind
directli
catalyt
site
proteas
near
site
spaciou
restrict
site
accommod
exclus
glycin
residu
substrat
ie
viral
polyprotein
ubiquitin
figur
show
inhibitor
present
bound
site
far
catalyt
triad
cyan
stick
evid
grow
zoonot
transmiss
bat
via
intermedi
host
human
start
get
interest
bat
coronaviru
main
proteas
drug
target
obvious
goal
cure
bat
coronaviru
infect
reservoir
bat
show
sign
diseas
carri
coronavirus
want
design
inhibitor
enzym
readi
case
zoonot
transmiss
bat
coronaviru
human
popul
idea
design
synthes
one
lead
compound
activ
immedi
enter
preclin
develop
case
major
epidem
outset
project
select
three
bat
coronavirus
repres
coronaviru
famili
alphacoronaviru
betacoronaviru
clade
c
betacoronaviru
clade
exclud
betacoronaviru
clade
b
bat
coronavirus
former
known
clade
b
alreadi
present
far
determin
crystal
structur
mpro
et
al
unpublish
xiao
et
al
unpublish
pdb
code
http
wwwrcsborgpdbsearchstructidsearchdo
http
wwwrcsborgpdbsearchstructidsearchdo
notic
antivir
michael
acceptor
compound
inhibit
enzym
predict
approach
came
emerg
found
inde
good
inhibitor
viru
cell
cultur
xiao
de
wild
muth
et
al
publish
btcov
turn
close
rel
amino
acid
sequenc
ident
similar
main
proteas
inact
mpro
howev
also
suggest
inhibitor
becom
broad
spectrum
present
ideal
one
would
like
one
antivir
hand
would
efficaci
coronaviru
famili
modif
good
activ
alphacoronavirus
develop
laboratori
main
proteas
mpro
proteas
plpro
prime
target
develop
antivir
newli
emerg
structur
describ
mpro
shortli
discoveri
new
viru
unfortun
atom
coordin
deposit
protein
data
bank
public
describ
mpro
inhibitor
michael
acceptor
compound
good
inhibitor
mpro
structur
proteas
new
viru
also
determin
enzym
featur
signific
differ
plpro
thu
stabil
oxyanion
intermedi
proteolyt
reaction
catalyz
plpro
appear
differ
mechan
propos
plpro
proteas
oxyanion
commonli
stabil
two
hydrogen
bond
enzym
one
donat
amid
catalyt
residu
glutamin
asparagin
five
six
residu
catalyt
cystein
plpro
correspond
propos
donat
hydrogen
bond
oxyanion
indol
nitrogen
plpro
tryptophan
replac
lack
capabl
interestingli
mutat
plpro
increas
peptidolyt
deubiquitin
activ
enzym
factor
respect
indic
proteas
optim
maximum
activ
evolut
viru
differ
plpro
plpro
includ
specif
subsit
subsit
accommod
arginin
residu
ubiquitin
complex
arginin
lysin
plpro
cleavag
site
viral
polyprotein
accordingli
subsit
domin
neg
charg
amino
acid
enzym
ie
site
site
howev
plpro
latter
residu
replac
posit
charg
henc
direct
extrapol
structur
complex
ubiquitin
recognit
enzym
possibl
rather
crystal
structur
complex
await
respons
crystallograph
commun
sar
outbreak
occasion
describ
swift
howev
realist
note
determin
structur
tgev
mpro
includ
inhibitor
complex
prior
sar
outbreak
respons
would
probabl
significantli
slower
nevertheless
hope
abl
review
illustr
import
role
play
crystallographi
elucid
structur
two
import
target
discoveri
develop
drug
main
proteas
mpro
proteas
plpro
fact
peptidomimet
inhibitor
mpro
design
basi
structur
knowledg
enzym
wherea
sever
inhibitor
identifi
use
crystal
structur
target
virtual
screen
chemic
librari
known
inhibitor
plpro
hand
mostli
base
origin
hit
identifi
screen
virtual
screen
campaign
recombin
enzym
subsequ
optim
accord
dock
plpro
crystal
structur
complex
target
howev
none
compound
direct
coronaviru
proteas
gone
complet
preclin
develop
program
mainli
sharp
declin
fund
countri
nonetheless
inhibitor
describ
far
good
start
point
develop
case
futur
zoonot
transmiss
coronavirus
human
popul
case
continu
mer
outbreak
occasion
argu
drug
discoveri
remain
domain
pharmaceut
industri
prioriti
academia
former
undoubtedli
better
howev
realiz
big
pharma
gener
littl
interest
emerg
rna
virus
typic
caus
rather
chronic
diseas
yet
virus
potenti
pose
big
threat
man
impress
taught
sar
coronaviru
well
advis
increas
prepared
view
increas
frequenc
outbreak
caus
virus
academ
institut
import
task
effort
increas
prepared
far
preclin
discoveri
phase
drug
develop
process
concern
macromolecular
crystallographi
undoubtedli
continu
play
major
role
effort
